Adeona Pharmaceuticals Inc. has swapped bosses as it continues testing new drugs for multiple sclerosis, fibromyalgia and Lou Gehrig’s disease. It’s also considering a new business focus and a name change.
Adeona Pharmaceuticals Inc. (NYSE Amex: AEN) said Thursday that it had started a Phase II clinical trial of Trimesta (oral estriol) for the treatment of cognitive dysfunction in multiple sclerosis in women.
Lycera Corp., a biopharmaceutical company creating innovative approaches to developing novel oral medicines to treat autoimmune diseases, today announced that it has reached the first milestone under its research collaboration with Merck, triggering a milestone payment.
The pharma startup Adeona Pharmaceuticals Inc. (AMEX: AEN), a developer of innovative medicines for serious central nervous system diseases, reported its third quarter 2011 financial results Monday.
Adeona Pharmaceuticals Inc. said Monday that the 150th patient has been enrolled in the randomized, double-blind, placebo-controlled, multi-center clinical trial of its Trimesta oral estriol drug candidate for relapsing-remitting multiple sclerosis in women.
If you’re out and about at the Island Lake Recreation Area Saturday, you might see a familiar face. WWJ’s John Bailey will be going for a long bike ride for charity.
Ann Arbor-based Adeona Pharmaceuticals Inc. (AMEX: AEN), a developer of medicines for serious central nervous system diseases, Monday reported its second quarter financial results for the period ended June 30, as well as updates since the beginning of the second quarter.
New research from the Grand Rapids-based Van Andel Research Institute demonstrates on the molecular level how the anti-malaria drug chloroquine represses inflammation, which may provide a blueprint for new strategies for treating auto-immune diseases from […]
Hunreds of folks responded to a posting on Facebook which noted an upcoming event to support the local chapter of Multiple Sclerosis society.
Ann Arbor-based Adeona Pharmaceuticals Inc. said Thursday that it had an agreement for the sale of 1,688,782 shares of its common stock at $2.0725 per share to a new institutional investor in a registered direct offering for $3.5 million in gross proceeds